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Abstract : The keyboard design is a novel phase I dose-finding method that is simple
and has good operating characteristics. This paper studies theoretical properties of the key-
board design, including the optimality of its decision rules, coherence in dose transition,
and convergence to the target dose. Establishing these theoretical properties explains the
mechanism of the design and provides assurance to practitioners regarding the behavior of
the keyboard design. We further extend the keyboard design to dual-agent dose-finding tri-
als, which inherit the same statistical properties and simplicity as the single-agent keyboard
design. Extensive simulations are conducted to evaluate the performance of the proposed
keyboard drug-combination design using a novel, random two-dimensional dose–toxicity sce-
nario generating algorithm. The simulation results confirm the desirable and competitive
operating characteristics of the keyboard design as established by the theoretical study. An
R Shiny application is developed to facilitate implementing the keyboard combination design
in practice.
KEY WORDS: Dose finding; drug combination; model-assisted design; maximum tolerated
dose; keyboard design; random drug-combination scenarios.
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1 Introduction
The objective of phase I clinical trials is to identify the maximum tolerated dose (MTD) of
a new drug, which is defined as the dose with the dose-limiting toxicity (DLT) probability
closest to the target toxicity rate. Conventionally, phase I dose-finding designs are generally
classified as algorithm-based and model-based [1, 2]. Algorithm-based designs implement
simple, prespecified rules to guide dose escalation and de-escalation. Examples include the
3+3 design, accelerated titration design [3], and the biased-coin design [4] and its variations
[5, 6]. The algorithm-based designs are easy to implement, but usually have unsatisfactory
operating characteristics and lack theoretical support [1, 2]. Model-based designs that utilize
some parametric dose–toxicity models to make dose escalation/de-escalation decisions have
been proposed to improve upon the performance of algorithm-based designs. The most
well-known example is the continual reassessment method (CRM) [7], which begins with a
prior guess of the dose–toxicity curve and then continuously updates the estimate of the
curve based on the accruing toxicity outcomes from patients in the trial to guide the dose
assignment. Various extensions of the CRM have been proposed, including dose escalation
with overdose control [8], time-to-event CRM [9], Bayesian model averaging CRM [10], partial
order CRM [11], and bivariate CRM [12]. For a comprehensive review of the CRM and
related methods, see the book by Cheung [13]. Compared to algorithm-based designs, model-
based designs typically have superior operating characteristics. However, because model-
based designs require repeated model fitting and estimation, they are more complicated to
implement and many practitioners view the decisions of the model-based designs as coming
from a “black box”.
A class of new designs, known as “model-assisted” designs, has drawn substantial at-
tention from practitioners because of its simplicity and desirable performance. Similar to
model-based designs, these designs utilize probability models for efficient decision making,
2
but their dose assignment rules can be pre-tabulated before the onset of the trial in a fashion
similar to the assignment rules of the algorithm-based designs. Examples of model-assisted
designs include the modified toxicity probability interval (mTPI) design [14], Bayesian opti-
mal interval (BOIN) design [15] and keyboard design [16]. In particular, the keyboard design
is a seamless improvement of the mTPI design that addresses the latter’s overdosing issue.
The keyboard design keeps the simplicity of the mTPI design, but has higher accuracy to
identify the MTD and substantially better overdose control [16].
The objective of this paper is to investigate the statistical properties of the keyboard
design, including optimality, coherence and consistency, which are not studied in the intro-
ductory paper[16]. Establishing these statistical properties is not only of theoretical interest,
but also of practical importance because it assures practitioners that the design has certain
guaranteed desirable behaviors. Specifically, we show that the decisions of the keyboard
design are optimal under the “0-1” loss function; the design is also long-memory coherent
in the sense that it never escalates (or de-escalates) the dose if the observed toxicity rate at
the current dose is higher (or lower) than the target toxicity rate; last, the keyboard design
is consistent in that its dose assignment converges to the target dose under large samples.
Armed with sound statistical properties and competitive operating characteristics, we
further extend the keyboard design to handle drug-combination trials. Numerous designs
have been proposed for finding the MTD for drug-combination trials: a design based on
the order of the restricted inference [17], a six-parameter model with continuous doses [18],
a copula-type regression model [19], latent contingency tables [20], a Bayesian hierarchical
model [21], sequential dose-finding strategy [22, 23], partial ordering CRM [11], adaptive ran-
domization [24], logistic regression model [25], change-point model with molecularly targeted
agents [26], another Bayesian optimal interval design [27], and Bayesian data augmentation
for late-onset toxicity [28], among others. Unlike most existing drug-combination designs, the
proposed keyboard combination design enjoys the same statistical properties, while retaining
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the same transparency and ease of implementation as the single-agent keyboard design. A
simulation study based on random and objective scenarios shows that the keyboard combi-
nation designs have very competitive performance compared to that of some existing, more
complicated designs. To facilitate the use of the designs, we also develop an R Shiny ap-
plication for implementing the keyboard combination designs that will be freely available at
http://www.trialdesign.org.
The rest of this paper is organized as follows. In Section 2, we review the keyboard
design and study its statistical properties. In Section 3, we extend the keyboard design
to two-agent combination trials. In Section 4, we propose a novel algorithm to generate
random two-dimensional dose–toxicity scenarios, and conduct extensive numerical studies to
investigate the operating characteristics of the keyboard combination design based on the
randomly generated scenarios. In Section 5, we illustrate how to use the R Shiny application
to design a drug combination trial. We provide some conclusions in Section 6.
2 The keyboard design and its statistical properties
2.1 The keyboard design
The keyboard design is a Bayesian dose-finding design originally proposed for phase I single-
agent trials. Let φ denote the target toxicity rate specified by an investigator, and pd ∈ (0, 1)
be the toxicity probability of the dose level d. The keyboard design starts by specifying a
target toxicity interval Itarget = (φ−1, φ+2) (referred to as the target key), where 1 and 2
denote tolerable deviations from φ such that any dose with a toxicity probability within that
interval can be practically viewed as the MTD. Then, the keyboard design populates this
interval toward both sides of the target key, forming a series of equally-wide keys that span
the range of 0 to 1 (see Figure 1). For example, given φ = 0.2, the target key may be defined
as (0.15, 0.25) with 1 = 2 = 0.05. Then, one key of width 0.1 is formed on the left side of the
target key, i.e., (0.05, 0.15), and seven keys of width 0.1, i.e., (0.25, 0.35), · · · , (0.85, 0.95),
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are formed on the right side of the target key. We denote the resulting intervals/keys as
I1, · · · , IK . In some cases, the DLT probability values at the two ends (e.g., < 0.05 or
> 0.95 in the example) may not be covered by the keys because they are not wide enough
to form a key of width 0.1. As explained in Yan et al.[16], ignoring these “residual” DLT
probabilities at the two ends does not pose any issue for decision making.
Assume that at a decision time, nd patients have been treated at the current dose d, and
yd of them have experienced DLT. A standard beta-binomial model is posited,
yd | pd ∼ Binomial(pd, nd),
pd ∼ Unif(0, 1),
where Unif(0, 1) serves as a non-informative prior distribution for pd. Given the observed
data Dd = (nd, yd), the posterior distribution of pd follows a beta distribution, pd|Dd ∼
Beta(yd + 1, nd − yd + 1). To make the dose assignment, the keyboard design identifies the
strongest key Imax that has the largest posterior probability, i.e.,
Imax = argmax
k∈{1,...,K}
{Pr(pd ∈ Ik |Dd)}.
In other words, the strongest key Imax represents the interval where the true value of pd is
most likely located. Graphically, the strongest key is the one with the largest area under the
posterior distribution curve of pd (see Figure 1). By continuously identifying the strongest
key Imax after each cohort, the dose-assignment rule for the next new cohort is described as
follows:
• If the strongest key is on the left side of the target key (denoted by Imax ≺ Itarget),
escalate the dose to the next higher level;
• If the strongest key is the target key (denoted by Imax ≡ Itarget), retain the current
dose level and stay at that level;
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• If the strongest key is on the right side of the target key (denoted by Imax  Itarget),
de-escalate the dose to the next lower level.
Because the decision of dose escalation and de-escalation only depends on the local data
at the current dose, the decision rule of the keyboard design can be pre-tabulated, making
the design transparent and easy to implement. Table 1 shows the dose escalation and de-
escalation rule for targets φ = 0.2 and 0.3.
2.2 Statistical properties
In this section, we study the statistical properties of the keyboard design. Let a ∈ {E ,R,D}
denote the three possible decisions, where E ,R, and D denote escalating, retaining and de-
escalating the dose, respectively, and let k∗ be the index of the key to which pd belongs. As
the keyboard design is consisted of two sequential actions (i.e., identify the strongest key
first and then make dose-assignment decisions according to the strongest key), under the
Bayesian decision theoretic framework, we define a “0-1” loss function as follows,
L(a, kˆ | Ik∗) = 1− `1(kˆ | Ik∗)`2(a | kˆ, Ik∗),
where `1(kˆ | Ik∗) is the loss function corresponding to the action of identifying the strongest
key, given by
`1(kˆ | Ik∗) = 1{kˆ = k∗} =
{
1, kˆ = k∗
0, kˆ 6= k∗
with 1{·} being the indicator function, and `2(a | kˆ, Ik∗) is the loss function corresponding
to the action of making dose-assignment decisions according to the strongest key, given by
`2(a | kˆ, Ik∗) = 1{a = E)1{Ikˆ ≺ Itarget}+ 1{a = R)1{Ikˆ ≡ Itarget}+ 1{a = D)1{Ikˆ  Itarget}
=

1, a = E and Ikˆ ≺ Itarget
1, a = R and Ikˆ ≡ Itarget
1, a = D and Ikˆ  Itarget
0, otherwise
.
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Since both `1(kˆ | Ik∗) and `2(a | kˆ, Ik∗) are “0-1” functions, L(a, kˆ | Ik∗) is also a “0-1”
loss function. Given the prior pd ∼ Unif(0, 1), it is easy to obtain that the prior model
probabilities of Ik are equal and that under each Ik, pd follows a uniform prior distribution
with the support Ik. The expected loss function is then
L(a, kˆ | Dd) =
K∑
k=1
L(a, kˆ | Ik) Pr(pd ∈ Ik | Dd)
=
K∑
k=1
{1− `1(kˆ | Ik)`2(a | kˆ, Ik)}Pr(pd ∈ Ik | Dd)
= 1−
K∑
k=1
`1(kˆ | Ik)`2(a | kˆ, Ik) Pr(pd ∈ Ik | Dd)
= 1−
K∑
k=1
1{kˆ = k}`2(a | kˆ, Ik) Pr(pd ∈ Ik | Dd)
Apparently, L(a, kˆ | Dd) is minimized if and only if Ikˆ = Imax = argmax
k∈{1,...,K}
{Pr(pd ∈ Ik |Dd)}
and a is taken as the correct action with respect to the location of Imax. Therefore, we
conclude that the decision rules of the keyboard designs correspond to an optimal rule.
Theorem 1 (Optimality). The dose escalation and de-escalation rule in the keyboard
designs is optimal in the sense that it minimizes the posterior expected “0-1” loss function
L(a, kˆ | Dd).
Cheung [13] introduced the concept of coherence and defined it as a design property
by which dose escalation (or de-escalation) is prohibited when the observed toxicity rate in
the most recently treated cohort is larger (or smaller) than the target toxicity rate. Liu and
Yuan [15] extended that concept and defined two different types of coherence: short-memory
coherence and long-memory coherence. They referred to the coherence proposed by Cheung
as short-memory coherence because it concerns the observations from only the most recently
treated cohort, ignoring the observations from the cohorts that were previously treated.
Long-memory coherence is defined as a design property by which dose escalation (or de-
escalation) is prohibited when the observed toxicity rate in the accumulative cohorts at the
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current dose is larger (or smaller) than the target toxicity rate. From a practical viewpoint,
long-memory coherence is more relevant because when clinicians determine whether a dose
assignment is practically plausible, they almost always base their decision on the toxicity
data that have accumulated from all patients, rather than only the most recent cohort (which
rarely includes more than three patients) treated at that dose. In addition, phase I trial
patients are very heterogenous and the observations from a cohort (≤ 3 patients) are highly
variable. Thus, it can be undesirable to evaluate whether dose escalation or de-escalation is
appropriate based on only a single cohort. For example, suppose the target DLT rate φ = 0.3
and at the current dose, one of the latest enrolled 3 patients experienced DLT but none of
6 patients previously treated at the same dose had DLT. As the overall observed DLT rate
at the current dose is 1/9, escalating the dose should not be regarded as an inappropriate
action, although it violates the short-memory coherence. It can be shown that the keyboard
design is long-memory coherent.
Theorem 2 (Coherence). The keyboard design is long-memory coherent in the sense
that the probability of escalating (or de-escalating) the dose if the observed toxicity rate in
the accumulative cohorts at the current dose is greater (or less) than the target toxicity rate,
that is, Pr(E | pˆd > φ,Dd) = 0, and Pr(D | pˆd < φ,Dd) = 0.
The proof of Theorem 2 is provided in Appendix B, which relies on an equivalent form of
the keyboard designs (as shown in Lemma A). However, since the keyboard designs integrate
all the accumulative data at the current dose when making decisions and does not allow dose
skipping, it is not necessarily short-memory coherent.
Coherence is a finite-sample property. Theorem 3 shows that the keyboard design has a
desirable large-sample convergence property.
Theorem 3 (Convergence). As the number of treated patients goes to infinity, the
dose assignment of the keyboard design converges almost surely to the dose level d with
pd ∈ Itarget.
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The proof of Theorem 3 is given in Appendix C. Although a good large-sample property
does not guarantee that a design will perform well in the small sample sizes of phase I clinical
trials, it provides a basic requirement for the design to perform well. If a design does not
converge to the target dose under large samples, it most likely will not perform well when
finding the target dose in small sample sizes.
3 Drug-combination keyboard designs
We now extend the keyboard design from single-agent trials to combination trials with
J levels of drug A and K levels of drug B. Let pjk denote the toxicity probability of the
combination of dose level j of drug A and dose level k of drug B, denoted as (j, k), 1 ≤ j ≤ J ,
1 ≤ k ≤ K. Let njk and yjk respectively denote the number of patients treated and the
number of patients who have experienced toxicity at d = (j, k). As the decision of dose
escalation/de-escalation of the single-agent keyboard design is solely based on the local data
at the current dose, its dose transition rule (as shown in Table 1) can be directly applied to
drug-combination trials. A single-agent trial using the keyboard design can be summarized
in the following three steps.
Step 1. The trial starts by treating the first cohort of patients at the lowest dose combination
(1, 1).
Step 2. At the current dose combination (j, k), given the observed data Djk = (njk, yjk), we
identify the strongest key Imax based on the posterior distribution of pj,k:
If Imax ≺ Itarget, we escalate the dose;
if Imax  Itarget, we de-escalate the dose;
otherwise, if Imax ≡ Itarget, we stay at the current dose.
Step 3. The process continues until the prespecified maximum sample size is achieved.
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For combination trials, the difficulty is that when we decide to escalate (de-escalate)
the dose, there is more than one option: we can escalate (de-escalate) either the dose level
of drug A, the dose level of drug B, or both simultaneously. To address this issue, we
define admissible dose escalation and de-escalation sets AE1 = {(j + 1, k), (j, k + 1)} and
AD1 = {(j−1, k), (j, k−1)}, which exclude diagonal dose movements. In addition, we define
admissible dose escalation and de-escalation sets that include diagonal dose movements,
namely, AE2 = {(j+1, k), (j, k+1), (j+1, k+1)} andAD2 = {(j−1, k), (j, k−1), (j−1, k−1)}.
Five dose assignment algorithms for drug-combination trials have been considered.
Algorithm 1: Fixed non-diagonal escalation/de-escalation (key1)
• Escalation: escalate to the dose combination that belongs to AE1 and has the highest
value of Pr(pjk ∈ Itarget|Djk).
• De-escalation: de-escalate to the dose combination that belongs to AD1 and has the
highest value of Pr(pjk ∈ Itarget|Djk).
Algorithm 2: Fixed non-diagonal escalation and diagonal de-escalation (key2)
• Escalation: escalate to the dose combination that belongs to AE1 and has the highest
value of Pr(pjk ∈ Itarget|Djk).
• De-escalation: de-escalate to the dose combination that belongs to AD2 and has the
highest value of Pr(pjk ∈ Itarget|Djk).
Algorithm 3: Fixed diagonal escalation/de-escalation (key3)
• Escalation: escalate to the dose combination that belongs to AE2 and has the highest
value of Pr(pjk ∈ Itarget|Djk).
• De-escalation: de-escalate to the dose combination that belongs to AD2 and has the
highest value of Pr(pjk ∈ Itarget|Djk).
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Algorithm 4: Randomized non-diagonal escalation/de-escalation (key4)
• Escalation: randomly escalate to the dose combination that belongs to any one of two
combination components in AE1 with randomization probabilities proportional to their
respective posterior probabilities Pr(pjk ∈ Itarget|Djk).
• De-escalation: de-escalate to the dose combination that randomly belongs to any one of
two combination components in AD1 with probabilities proportional to their respective
posterior probabilities Pr(pjk ∈ Itarget|Djk).
Algorithm 5: Randomized diagonal escalation/de-escalation (key5)
• Escalation: randomly escalate to the dose combination that belongs to any one of two
combination components in AE2 with randomization probabilities proportional to their
respective posterior probabilities Pr(pjk ∈ Itarget|Djk).
• De-escalation: randomly de-escalate to the dose combination that belongs to any one of
two combination components in AD2 with the randomization probabilities proportional
to their respective posterior probabilities Pr(pjk ∈ Itarget|Djk).
For algorithms 1–3 with fixed allocation rules, if there are multiple optimal dose com-
binations with the same value of Pr(pjk ∈ Itarget|Djk), we randomly choose one with equal
probability.
The trial is completed when the maximum sample size is reached. Given all observed
data, we use matrix isotonic regression [30] to obtain the estimate of pjk and select the MTD
as the combination with a toxicity estimate that is closest to the target. When there are ties,
we randomly choose one as the MTD. For patient safety, during trial conduct, we apply the
following overdose control rule: whenever a dose satisfies Pr(pjk > φ|Djk) ≥ c (i.e., the dose
is overly toxic), where c is a prespecified probability cutoff, we eliminate that dose from the
trial. In addition, we impose an early stopping rule: if the lowest dose combination (1, 1) is
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overly toxic, i.e., Pr(p11 > φ|D11) ≥ c, we terminate the trial early. Throughout the paper,
we set c = 0.95.
4 Numerical study
4.1 A random matrix scenario generator
The evaluation and comparison of phase I designs are often based on a limited number of
prespecified dose–toxicity scenarios, which is prone to favor a specific design intentionally or
unintentionally. To avoid that issue, Clertant and O’Quigley [31] proposed a pseudo-uniform
algorithm to generate random toxicity scenarios for more objective and unbiased comparisons
for single-agent phase I designs. To the best of our knowledge, there is no accessible algorithm
for generating random scenarios for a two-dimensional dose matrix, where the partial order
constraint for a two-dimensional toxicity space poses major difficulty. To fill this gap, we
have developed a fast and efficient algorithm to generate random combination scenarios as
described below.
Algorithm: a random matrix scenario generator
Step 1: Uniformly choose a dose level (j, k), 1 ≤ j ≤ J, 1 ≤ k ≤ K from the J × K drug-
combination space, and set pjk = φ.
Step 2: Given the dose combination (j, k), specify a “pivotal” path from p11 to p1K : p11 →
... → pj1 → ... → pjk → ... → pjK → ... → pJK . The doses in the pivotal path are
monotonically ordered in toxicity and partition the J×K dose matrix into upper block
(UB above the path) and lower block (LB under the path) matrices.
Step 3: Generate the toxicity probabilities for the doses on the pivotal path as follows: generate
an ordered uniformly-distributed random sample of toxicity probabilities with length
j + k − 2 from Unif(0, φ) and assign them to (p11, · · · , pj1, · · · , pjk−1), and generate
an ordered uniformly-distributed random sample with length J + K − j − k from
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Unif(φ, pmax) and assign them to (pjk+1, · · · , pjK , · · · , pJK), where pmax is the upper
bound for the maximum toxicity rate and is generated from a Beta distribution with
mean µ and variance µ(1−µ). In this paper, we take µ = 1−exp{−(J×K)/8}, which
can satisfactorily provide the upper bound for pJK .
Step 4: Generate the toxicity probabilities for the doses located in the UB and LB as follows:
– For the UB, from row j−1 to row 1, sequentially generate pj′k′ ∼ Unif(pj′k′−1, pj′+1,k′), j′ =
j − 1, . . . , 1, k′ = 2, . . . , K.
– For the LB, from row j+1 to row J , sequentially generate pj′k′ ∼ Unif(pj′−1,k′−1, pj′k′+1), j′ =
j + 1, . . . , J, k′ = K − 1, . . . , 1.
The resulting toxicity probability matrix meets the requirement of a partial order for drug
combinations. For illustration of the proposed random matrix scenario generator, a concrete
example of generating a 3× 3 toxicity probability matrix is given in Appendix D. Under the
above algorithm, one dose has the toxicity probability equal to the target φ (i.e., step 1);
however, as the toxicity probabilities of other doses are randomly generated, some may be
fairly close (although not exactly equal) to φ. As a dose with the toxicity probability within
[φ − 1, φ + 2] is deemed acceptable (as the MTD), and the proposed algorithm is able to
produce multiple MTDs in the randomly generated toxicity probability matrix.
4.2 Simulation configuration
We conduct simulation studies to investigate the performance of the drug-combination key-
board designs based on the random matrix scenarios proposed in Section 4.1. We consider
two target toxicity rates (φ = 0.2 or 0.3), three sizes of dose matrices (2× 4, 3× 5 or 4× 4),
and three values for the total number of MTDs (1, 2 or 3 MTDs). This results in 16 pos-
sible configurations, noting that for the 2× 4 combinations, we consider 1 or 2 MTDs. For
each simulation configuration, we generate 1000 random scenarios. For visualization, given
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the target toxicity rate φ = 0.2, Figure 2 shows 50 randomly selected dose–toxicity curves
for each row and each column for the 4 × 4 drug combination, while Figure 3 displays the
distributions of the toxicity probabilities by dose combination level from the 1000 random
scenarios for the 2 × 4 drug combination. These values exhibit a variety of dose–toxicity
surface shapes and spacings.
We compare the proposed keyboard combination designs to the partial order CRM
method (POCRM) [11]. For the POCRM, we choose six partial orderings as recommended
by Hirakawa et al.[32], and assign an equal prior probability to them. The skeleton values
are generated according to the algorithm of Lee and Cheung [13] using the getprior function
in the R package “dfcrm”. Specifically, for 2× 4 combinations, we use getprior(0.05,φ,4,8);
for 3 × 5 combinations, we use getprior(0.05,φ,7,15); and for 4 × 4 combinations, we use
getprior(0.05,φ,7,16). All simulation results regarding POCRM are obtained using the
R package “pocrm”. For the keyboard design, we take 1 = 2 = 0.03 for φ = 0.2 and
1 = 2 = 0.05 for φ = 0.3, and the resulting dose escalation/de-escalation rules are shown
in Table 1. The maximum sample size is set at 48 for scenarios with 2× 4 dimension and at
60 for scenarios with 3 × 5 and 4× 4 dimensions, where the cohort size in all cases is fixed
at one for both designs. For fair comparisons, we apply the early stopping rule as discussed
in Section 3 to both designs.
4.3 Simulation results
Tables 2 - 4 present simulation results for the 2× 4, 3× 5 and 4× 4 drug combinations, re-
spectively. For a comprehensive comparison, we calculate the following performance metrics
across each 1000 random scenarios for POCRM and the keyboard design.
MTD selection : The percentage of correct selection (PCS) is defined as the percentage
of simulated trials in which the dose combination selected as the MTD has a true toxicity
probability that lies within the interval [φ − 1, φ + 2]. Such a metric quantifies the iden-
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tification accuracy of a design. In all cases, all keyboard combination designs outperform
the POCRM in terms of PCS. For example, when φ = 0.2 with two MTDs in the 3 × 5
combination trials (Table 3), the PCS of POCRM is 25.1%, while key1 to key5 have 8.0%,
7.8%, 7.4%, 7.8% and 7.0% more chances to identify the correct MTDs, respectively. The
PCS difference among five versions of the keyboard combination design is not significant.
Patient allocation : The percentage of correct assignment (PCA) is defined as the
percentage of patients who are assigned to a dose combination with a true toxicity probability
that lies within the interval [φ−1, φ+2]. Such a metric quantifies the treatment efficiency of
a design. In general, all five versions of the keyboard combination designs have larger PCAs
than the POCRM. However, the keyboard designs with fixed allocation rules perform slightly
better than those with random allocation rules on average. For example, when φ = 0.3 with
three MTDs in the 3 × 5 combination trials (Table 3), key1 to key3 have respective values
of 32.12%, 30.72%, and 29.68%, while key4 and key5 have respective values of 27.36% and
25.97%.
Overdose and underdose control : The percentage of overdose assignment is defined
as the percentage of patients who are assigned to a dose combination with a true toxicity
probability that is larger than φ + 2. The percentage of underdose assignment is defined
as the percentage of patients who are assigned to a dose combination with a true toxicity
probability that is less than φ − 1. Such two metrics respectively quantify the safety and
conservativeness of a design. For overdosing, in general, the POCRM allocates fewer patients
to doses above the MTD than the keyboard designs. However, for underdosing, the POCRM
tends to treat more patients at doses below the MTD.
Incoherent index : Long-memory incoherence in the escalation percentage is defined
as the percentage of dose escalation with pˆjk > φ. Such a metric can partly quantify the
aggressiveness of a design. According to Table 5, we can conclude that the POCRM is not
long-memory coherent. A specific example showing the incoherence (including both short
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and long memory) of the POCRM can be found in Appendix E. For example, after patient
7 was treated at dose (1, 4), 1/1 patient had DLT at that dose, and the POCRM escalated
the dose to (3, 4). When patient 9 was treated at dose (1, 4), 1/2 patients had DLT, and
the POCRM again escalated the dose to (3, 3).
In summary, the simulation results show that the keyboard combination designs generally
outperform the POCRM in terms of MTD identification accuracy and treatment efficiency.
Among the five versions of keyboard designs, the designs (key1–key3) based on fixed alloca-
tion rules usually lead to more patients being treated at the MTDs than those (key4–key5)
that use randomization. We recommend key1 and key2 for general drug-combination trials.
While key2 has larger admissible dose escalation and de-escalation sets, key1 tends to be
more efficient yet slightly more aggressive than key2.
5 Web application
To facilitate the use of the keyboard combination design, we develop an easy-to-implement
web application using R Shiny. Figure 4 shows the graphical user interface of the application.
After users input their design parameters (e.g., the maximum sample size, cohort size, and the
dose combination scenarios), the web application generates the operating characteristics of
the keyboard combination design that can be included in the trial protocol. When conducting
the trial, users can simply choose the “Next Dose” button, and the R Shiny application
will recommend the dose combination to be assigned to the next cohort of patients based
on the updated accumulated information. Our web application will be freely available at
http://www.trialdesign.org. A reference manual is also provided at that website for
illustration and implementation.
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6 Conclusion
The statistical properties of the keyboard design have been comprehensively investigated
in this paper. In particular, we have shown that the keyboard design possesses optimal
allocation rules such that the posterior expected “0-1” loss function can be minimized. The
dose transition is long-memory coherent in the sense that when the observed toxicity rate
at the current dose is larger (smaller) than the target toxicity rate, the keyboard design
prevents the next patients from receiving overly toxic (subtherapeutic) doses. In addition,
the keyboard design exhibits a convergence property that is similar to that of the standard
interval designs, and its asymptotic patient allocation converges to the target dose level.
We have further proposed a class of two-dimensional keyboard designs for dose finding in
phase I drug-combination trials. The satisfactory performance and operating characteristics
of the keyboard combination designs have been demonstrated numerically based on random
combination scenarios. From statistical and clinical viewpoints, the proposed combination
designs are simple and easy to understand, and we have also developed an R Shiny application
for practitioners to use to easily implement the method. Due to the nature of model-assisted
designs, the proposed designs are robust against any arbitrary toxicity surfaces of the drug
combinations, like the BOIN combination design [27]. Furthermore, the model-assisted key-
board design, without implementing a start-up phase, has comparable performance (better
performance in terms of PCS and PCA) compared with the model-based design such as the
POCRM. In conclusion, the proposed keyboard combination design offers a middle ground
between the existing algorithm-based designs and fully model-based designs.
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Figure 1: An example based on the observed data (yd, nd) = (2, 5) for the target toxicity rate
of 0.2 to demonstrate the target key Imax and the strongest keys Itarget. In this example, the
strongest key (i.e., (0.35, 0.45)) lies on the right side of the target key (i.e., (0.15, 0.25)), so
dose escalation is warranted.
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Figure 2: Four rows/columns of 50 randomly selected dose–toxicity curves for the 4×4 drug
combination with the target toxicity rate φ = 0.2.
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Figure 3: Empirical distribution of the 1000 simulated toxicity probabilities by dose level of
the 2× 4 drug combination with the target toxicity rate φ = 0.2.
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Table 1: Escalation and de-escalation rules for the keyboard design for up to 16 patients
treated at the current dose.
Number of patients treated at the current dose
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
φ = 0.2 with the target key = (0.17, 0.23)
Escalate if number of DLTs ≤ 0 0 0 0 0 1 1 1 1 1 1 2 2 2 2 2
De-escalate if number of DLTs ≥ 1 1 1 1 2 2 2 2 3 3 3 3 3 4 4 4
φ = 0.3 with the target key=(0.25, 0.35)
Escalate if number of DLTs ≤ 0 0 0 0 1 1 1 1 2 2 2 2 3 3 3 3
De-escalate if number of DLTs ≥ 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6
Table 2: Average performance of the six designs across 1000 random scenarios for the 2× 4
drug combination.
Target toxicity rate φ = 0.2
With one MTD
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 30.66 33.71 33.38 33.18 32.93 32.67
Correct assignment % 20.99 26.55 25.94 25.94 23.46 22.73
Overdose assignment% 32.15 32.93 31.23 33.51 37.79 35.36
Underdose assignment% 46.86 40.52 42.83 40.55 38.75 41.91
With two MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 43.65 44.14 44.68 43.46 43.28 42.83
Correct assignment % 34.31 46.51 37.00 44.67 32.37 31.22
Overdose assignment% 25.49 28.01 26.35 25.97 34.74 32.05
Underdose assignment% 40.20 25.48 36.65 29.36 32.89 36.73
Target toxicity rate φ = 0.3
With one MTD
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 21.48 38.44 38.38 37.76 37.13 37.44
Correct assignment % 14.71 27.22 26.60 26.37 23.88 23.59
Overdose assignment% 33.66 38.57 34.87 39.52 40.71 36.93
Underdose assignment% 41.35 38.63 42.17 38.93 39.25 42.03
With two MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 29.69 52.03 51.99 50.83 50.76 48.91
Correct assignment % 23.08 38.80 37.63 36.79 32.26 31.85
Overdose assignment% 38.36 29.80 26.35 31.34 34.04 31.29
Underdose assignment% 38.56 31.40 36.02 31.87 36.86 36.90
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Table 3: Average performance of the six designs across 1000 random scenarios for the 3× 5
drug combination.
Target toxicity rate φ = 0.2
With one MTD
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 16.38 25.07 24.85 24.92 25.41 25.02
Correct assignment % 10.19 17.72 17.24 17.43 16.73 16.07
Overdose assignment% 31.29 36.63 34.47 37.65 41.37 38.06
Underdose assignment% 58.52 45.65 48.29 44.92 41.90 45.87
With two MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 25.10 33.14 32.96 32.45 32.91 32.16
Correct assignment % 18.49 24.45 23.63 23.26 21.85 20.64
Overdose assignment% 27.89 34.78 32.42 36.56 41.03 37.18
Underdose assignment% 53.62 40.77 43.95 40.18 37.12 42.18
With three MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 32.43 39.73 39.60 39.08 39.06 38.37
Correct assignment % 25.37 30.79 29.78 29.24 27.21 25.81
Overdose assignment% 24.68 24.48 24.13 34.55 39.67 35.71
Underdose assignment% 49.95 44.73 46.09 36.21 33.12 38.48
Target toxicity rate φ = 0.3
With one MTD
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 22.39 28.71 28.50 27.97 29.65 29.13
Correct assignment % 13.93 18.32 17.74 17.47 17.19 16.41
Overdose assignment% 33.66 38.57 34.87 39.52 40.71 36.93
Underdose assignment% 52.41 43.11 47.39 43.01 42.10 46.66
With two MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 29.03 38.55 38.53 37.35 37.07 37.97
Correct assignment % 20.43 25.21 24.24 23.43 20.89 20.72
Overdose assignment% 28.33 37.19 33.03 39.00 40.32 35.80
Underdose assignment% 51.24 37.60 42.73 37.57 38.79 43.48
With three MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 36.38 46.92 46.68 45.38 46.17 45.69
Correct assignment % 27.26 32.12 30.72 29.68 27.36 25.97
Overdose assignment% 25.61 34.38 30.24 36.69 38.39 33.66
Underdose assignment% 47.13 33.50 39.04 33.63 34.25 36.55
26
Table 4: Average performance of the six designs across 1000 random scenarios for the 4× 4
drug combination.
Target toxicity rate φ = 0.2
With one MTD
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 16.21 24.71 24.45 24.69 24.89 24.31
Correct assignment % 9.12 17.07 16.54 16.81 16.10 15.37
Overdose assignment% 20.74 38.36 36.06 39.14 42.21 38.68
Underdose assignment% 70.14 44.57 47.40 44.05 41.69 45.95
With two MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 25.21 32.93 32.75 32.34 32.36 31.64
Correct assignment % 15.70 23.62 22.74 22.42 21.01 19.71
Overdose assignment% 15.34 35.00 32.45 36.59 41.07 37.14
Underdose assignment% 68.96 41.38 44.81 40.99 37.92 43.15
With three MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 34.74 39.15 39.05 38.44 38.01 37.51
Correct assignment % 22.73 29.57 28.53 27.04 25.92 24.41
Overdose assignment% 12.83 34.08 31.18 35.63 41.08 36.95
Underdose assignment% 64.44 36.35 40.29 37.33 33.00 38.64
Target toxicity rate φ = 0.3
With one MTD
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 21.55 28.27 27.93 27.67 28.70 27.99
Correct assignment % 12.84 17.70 17.02 16.85 16.45 15.67
Overdose assignment% 23.76 40.31 36.21 41.47 41.39 37.41
Underdose assignment% 63.40 41.99 46.77 41.68 42.16 46.92
With two MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 21.72 37.86 37.44 36.54 37.47 36.59
Correct assignment % 12.96 24.31 23.13 22.30 20.95 19.68
Overdose assignment% 23.69 37.78 33.26 39.63 40.36 35.63
Underdose assignment% 63.35 37.91 43.61 38.07 38.69 44.69
With three MTDs
POCRM Key1 Key2 Key3 Key4 Key5
Correct selection% 39.93 45.35 45.12 43.87 44.60 43.86
Correct assignment % 26.06 30.33 29.02 27.79 25.82 24.42
Overdose assignment% 14.09 36.34 31.54 38.61 39.55 34.46
Underdose assignment% 59.85 33.33 39.44 33.60 34.63 41.12
27
Table 5: Percentage of occurring long-memory incoherence in escalation for the POCRM
among 1000 simulated trials.
Drug combination Target rate One MTD Two MTDs Three MTDs
2× 4 0.2 0.53 0.61 NA
0.3 0.92 0.99 NA
3× 5 0.2 1.72 1.28 1.35
0.3 2.32 2.62 2.76
4× 4 0.2 3.74 3.65 3.72
0.3 3.09 3.25 3.30
Note: “NA” denotes not applicable.
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Figure 4: Web application for the keyboard combination design.
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Appendix
A Lemma A: Simplified rule for the keyboard designs
The keyboard designs introduced in Section 2 adopt K keys I1, . . . , IK for decision making.
In this Lemma, we show that the decision-making procedure of the keyboard designs can be
further simplified to designs using only three keys.
Lemma A. The keyboard designs essentially determine which one of the following keys
has the largest posterior probability
K1 : pd ∈ (φ− 21 − 2, φ− 1), K0 : pd ∈ (φ− 1, φ+ 2), K2 : pd ∈ (φ+ 2, φ+ 1 + 22),
where φ + 1 + 22 < 1 and φ − 21 − 2 > 0, and the prior pd ∼ Unif(0, 1). The dose
assignment decisions in the keyboard design are then
• Escalate the dose if 1 = argmax
i∈{0,1,2}
{Pr(Ki | Dd)};
• De-escalate the dose if 2 = argmax
i∈{0,1,2}
{Pr(Ki | Dd)};
• Retain the current dose if 0 = argmax
i∈{0,1,2}
{Pr(Ki | Dd)}.
Proof. Let k† denote the index of the target key among the K prespecified keys, i.e., Ik† =
Itarget = K0. The posterior probability of event K0 (or Ik†) is given by
Pr(K0 | Dd) =
∫
1{pd ∈ K0}f(pd | Dd)dpd
∝
∫ φ+2
φ−1
pydd (1− pd)nd−yddpd
∝ ξyd0 (1− ξ0)nd−yd ≡ g(ξ0)
where the last equality is due to the mean value theorem for integrals and ξ0 is a toxicity
probability that lies within (φ − 1, φ + 2). Similarly, the posterior probabilities of events
K1 and K2 can be represented as Pr(K1 | Dd) ∝ g(ξ1) and Pr(K2 | Dd) ∝ g(ξ2), respectively,
where ξ1 ∈ (φ− 21 − 2, φ− 1) and ξ2 ∈ (φ+ 2, φ+ 1 + 22), ξ1 < ξ0 < ξ2.
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Three cases are considered.
• For dose retainment,
– if 0 = argmax
i∈{0,1,2}
{Pr(Ki | Dd)}, then g(ξ0) ≥ max(g(ξ1), g(ξ2)). Given a key k with
Ik ≺ Ik†−1(or K1), we have Pr(pd ∈ Ik | Dd) ∝ g(ξ′), where ξ′ ∈ Ik and ξ′ < ξ1.
Then, according to the unimodality of the binomial likelihood, it is easy to obtain
that g(ξ′) < g(ξ1) < g(ξ0) and thus Pr(Ik | Dd) < Pr(Ik† | Dd). Similarly, given a
key k with Ik  Ik†+1(or K2), we can also show that Pr(Ik | Dd) < Pr(Ik† | Dd).
Therefore, the keyboard designs based on three keys imply those based on K keys
in terms of dose retainment.
– if Imax ≡ Itarget, then we immediately obtain that 0 = argmax
i∈{0,1,2}
{Pr(Ki | Dd)}.
Therefore, the keyboard designs based on K keys also imply those based on three
keys in terms of dose retainment.
• For dose escalation,
– if 1 = argmax
i∈{0,1,2}
{Pr(Ki | Dd)}, then g(ξ1) > g(ξ0) > g(ξ2) which is due to the
unimodality of the binomial likelihood, leading to Imax ≺ Itarget. Therefore, the
keyboard designs based on three keys imply those based on K keys in terms of
dose escalation.
– if Imax ≺ Itarget, then using the unimodality of the binomial likelihood again, we
obtain that g(ξ2) < g(ξ0) < g(ξ1) < g(ξ
′), where Pr(Imax | Dd) ∝ g(ξ′), leading to
1 = argmax
i∈{0,1,2}
{Pr(Ki | Dd)}. Therefore, the keyboard designs based on K keys also
imply those based on three keys in terms of dose escalation.
• For dose de-escalation, it can be shown similarly that the keyboard designs based on
three keys are equivalent to those based on K keys in terms of dose de-escalation.
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B Proof of Theorem 2 - Coherence
Proof. According to Lemma A, the decision of the keyboard designs is solely based on the
maximum value among {g(ξ1), g(ξ0), g(ξ2)}, or equivalently, among {Pr(K1 | Dd)}, {Pr(K0 |
Dd)}, {Pr(K2 | Dd)}. Since the binomial likelihood g(pd) = pydd (1− pd)nd−yd is maximized at
pˆd = yd/nd, we have the following possible scenarios.
• If pˆd ≤ φ− 1, according to the unimodality of the binomial likelihood, we always have
g(ξ2) < g(ξ0), which indicates that Pr(K2 | Dd) < Pr(K0 | Dd), then the chance for
dose de-escalation is zero.
• If pˆd ≥ φ+ 2, according to the unimodality of the binomial likelihood, we always have
g(ξ1) < g(ξ0), which indicates that Pr(K1 | Dd) < Pr(K0 | Dd), then the chance for
dose escalation is zero.
• If φ ≤ pˆd < φ+ 2, we define the following difference function,
d(1, 2) = Pr(K0 | Dd)− Pr(K1 | Dd)
∝
∫ φ+2
φ−1
g(pd)dpd −
∫ φ−1
φ−21−2
g(pd)dpd.
Differentiating d(1, 2) with respect to 1, we have
∂d(1, 2)
∂1
= 2g(φ− 1)− 2g(φ− 21 − 2) > 0,
as the mode of g(pd) is pˆd and pˆd ≥ φ− 1. Therefore, d(1, 2) is an increasing function
of 1, and we only need to consider the case when 1 = 0. That is, if we can show that
d(0, 2) > 0 then based on the monotonicity of d(1, 2), we have d(1, 2) > d(0, 2) > 0.
When 1 = 0, the difference function reduces to
d(0, 2) ∝
∫ φ+2
φ
g(pd)dpd −
∫ φ
φ−2
g(pd)dpd.
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Again, differentiating d(0, 2) with respect to 2, we have
∂d(0, 2)
∂2
∝ g(φ+ 2)− g(φ− 2).
Denote the log-likelihood ratio of φ+ 2 versus φ− 2 as
l(yd, nd, 2) = ln
g(φ+ 2)
g(φ− 2)
= yd ln(φ+ 2) + (nd − yd) ln(1− φ− 2)
−yd ln(φ− 2)− (nd − yd) ln(1− φ+ 2),
which is an increasing function with respect to yd. Since pˆd ∈ (φ, φ + 2) and yd is
a integer value, it suffices to show that d(0, 2) > 0 with Dd = (yd + 1, nd), pˆd =
(yd + 1)/nd, and φ = yd/nd.
Next, we consider two cases:
(a) When φ < 0.5, taking the derivative of l(yd, nd, 2) with respect to 2, we have
∂l(yd + 1, nd, 2)
∂2
=
yd + 1
φ+ 2
− nd − yd − 1
1− φ− 2 +
yd + 1
φ− 2 −
nd − yd − 1
1− φ+ 2
=
222(nd − 2φnd − 1) + 2φ(1− φ)
(φ+ 2)(1− φ− 2)(φ− 2)(1− φ+ 2) .
Since φ− 2 > 0, we have
∂l(yd + 1, nd, 2)
∂2
>
∂l(yd + 1, 1, φ)
∂2
=
2(φ− φ2 − 2φ3)
(φ+ 2)(1− φ− 2)(φ− 2)(1− φ+ 2) ≥ 0.
Therefore, l(yd+1, nd, 2) is an increasing function of 2, which implies that l(yd+
1, nd, 2) > l(yd + 1, nd, 0) = 1. As a result,
d(1, 2) > d(0, 2) > d(0, 0) = 0.
(b) When φ ≥ 0.5, we have φ + 2 ≤ 1. Since d(0, 2) is a unimodal function with
respect to 2, we just need to focus on the two end points 2 = 0 and 2 = 1− φ.
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If 2 = 0, it is easy to observe that d(0, 0) = 0. If 2 = 1− φ, then
d(0, 1− φ) ∝
∫ 1
φ
g(pd)dpd −
∫ φ
2φ−1
g(pd)dpd,
and
∂d(0, 1− φ)
∂φ
∝ 2g(2φ− 1)− 2g(φ) ≤ 0,
given that φ ≥ 0.5, yd = ndφ, and g(·) is evaluated at Dd = (yd + 1, nd). As a
result, d(0, 1− φ) is a decreasing function of φ, and
d(1, 2) > d(0, 2) > min(d(0, 0), d(0, 1− φ)) ≥ d(0, 0) = 0.
In summary, d(1, 2) = Pr(K0 | Dd)− Pr(K1 | Dd) > 0, the chance for dose escalation
is zero.
• If φ−1 < pˆd < φ, based on a mimicking approach of the case in which φ ≤ pˆd < φ+2,
it can be shown that Pr(K2 | Dd) < Pr(K0 | Dd) and the chance for dose de-escalation
is zero.
Based on the above argument, the keyboard design is long-memory coherent.
C Proof of Theorem 3 - Convergence
Proof. In what follows, we provide a heuristic proof of the convergence of the keyboard
designs. As the sample size increases, it is well known that the posterior distribution of pd
under the beta-binomial model asymptotically converges to a normal distribution:
pd ∼ N(pˆd, [I(Dd)]−1) (1)
where pˆd = arg maxpdf(Dd|pd)f(pd) and [I(Dd)]−1 = −{ ∂
2
∂p2d
log[f(Dd|pd)f(pd)]}|pd=pˆd . Here,
f(Dd|pd) is the likelihood function of the data at the dose level d and f(pd) is the corre-
sponding prior density, pd ∼ Unif(0, 1).
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From the above, we see that the mode of the asymptotic distribution is a consistent
estimate of pd. That is, under large samples, the strongest key Imax converges to the key Ik
with pd ∈ Ik. Therefore, based on the keyboard design rules,
• if Imax ≺ Itarget, we escalate the dose, and I ′max, the strongest key of the next dose
level, is on the right side of Imax;
• if Imax  Itarget, we de-escalate the dose, and I ′max, the strongest key of the next dose
level, is on the left side of Imax.
After a long run, as long as the next dose level hits the dose with pd ∈ Itarget, according to
the asymptotic posterior distribution of pd, we have Pr(Imax = Itarget | Dd) = 1 as nd →∞.
As a result, the asymptotic dose movement of the keyboard designs can only settle on a dose
with the toxicity probability pd within the target key Itarget.
D An example of generating a random 3 × 3 toxicity
probability matrix.
For illustration of the proposed random scenario generator for drug-combination trials, we
consider a 3× 3 toxicity probability matrix with the target toxicity rate φ = 0.2,p11 p12 p13p21 p22 p23
p31 p32 p33
 .
According to the proposed algorithm as described in Section 4.1,
Step 1: Randomly choose an element from the 3 × 3 matrix with an equal probability (of
1/9) and set it as φ. For instance, dose combination (2, 2) is selected, and now, the
probability matrix is p11 p12 p13p21 p22 = 0.20 p23
p31 p32 p33

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Step 2: Specify the pivotal path, given by p11 → p21 → p22 → p23 → p33, as shown below.p11 p12 p13p21 p22 = 0.20 p23
p31 p32 p33

Step 3: Generate the toxicity probabilities for the doses on the pivotal path as follows. Gen-
erating (p11, p21) from Unif(0, 0.2), we obtain p11 = 0.01 and p21 = 0.15. As the upper
bound of pmax = 1 − exp(−3/8) = 0.68, we generate (p23, p33) from Unif(0.20, 0.68)
and obtain p23 = 0.38 and p33 = 0.55. Now, the toxicity probability matrix isp11 = 0.01 p12 p13p21 = 0.15 p22 = 0.20 p23 = 0.38
p31 p32 p33 = 0.55

Step 4: For the upper block (UB), p12 can be generated from Unif(1,0.01,0.20)=0.10, and p13
from Unif(1,0.10,0.38)=0.23. Thus, we completed the UB part, and the matrix isp11 = 0.01 p12 = 0.10 p13 = 0.23p21 = 0.15 p22 = 0.20 p23 = 0.38
p31 p32 p33 = 0.55

Similarly, for the lower block (LB), p32 can be generated by Unif(1,0.2,0.55)=0.42 and
p31 by Unif(1,0.15,0.42)=0.27. The final matrix isp11 = 0.01 p12 = 0.10 p13 = 0.23p21 = 0.15 p22 = 0.20 p23 = 0.38
p31 = 0.27 p32 = 0.42 p33 = 0.55

If we set 1 = 2 = 0.03, we can see that we generated a random matrix having two MTDs,
i.e., p13 and p22.
E An example of incoherence for POCRM
This example illustrates the violation of incoherence for POCRM. We consider a 4×4 matrix
setting. The target toxicity rate is 0.30 and the true toxicity probability matrix is
{(i, j)}4i,j=1 =

0.50 0.55 0.60 0.70
0.15 0.30 0.50 0.60
0.10 0.12 0.30 0.45
0.06 0.08 0.10 0.15

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Following [11], three orders are prespecified for the POCRM,
Order 1 : (1, 1)→ (1, 2)→ (2, 1)→ (1, 3)→ (2, 2)→ (3, 1)→ (1, 4)→ (2, 3)→
(3, 2)→ (4, 1)→ (2, 4)→ (3, 3)→ (4, 2)→ (3, 4)→ (4, 3)→ (4, 4)
Order 2 : (1, 1)→ (2, 1)→ (1, 2)→ (1, 3)→ (2, 2)→ (3, 1)→ (4, 1)→ (3, 2)→
(2, 3)→ (1, 4)→ (2, 4)→ (3, 3)→ (4, 2)→ (4, 3)→ (3, 4)→ (4, 4)
Order 3 : (1, 1)→ (2, 1)→ (1, 2)→ (3, 1)→ (2, 2)→ (1, 3)→ (4, 1)→ (3, 2)→
(2, 3)→ (1, 4)→ (4, 2)→ (3, 3)→ (2, 4)→ (4, 3)→ (3, 4)→ (4, 4)
The maximum sample size is 40, and we utilize “pocrm.sim” in the R package “pocrm” to
simulate one trial based on the random seed of 2. The other implementation details of the
POCRM are exactly the same as those used in the reference manual of “pocrm”.
We provide step-by-step movements of POCRM in Table A1. From the table, we can see
that for this simulated trial, there are 4 incoherent dose movements.
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Table A1: Dose movements of the POCRM for a 4× 4 combination trial with φ = 0.3.
Patient Dose DLT pˆjk Order Action Incoherent Patient Dose DLT pˆjk Order Action Incoherent
1 (1, 1) 0 0/1 NA E NA 21 (4, 2) 1 1/2 3 D N
2 (1, 2) 0 0/1 NA E NA 22 (2, 3) 1 1/2 3 D N
3 (2, 1) 0 0/1 NA E NA 23 (4, 1) 1 1/1 1 D N
4 (1, 3) 0 0/1 NA E NA 24 (2, 2) 0 0/2 1 E N
5 (2, 2) 0 0/1 NA E NA 25 (3, 1) 1 1/2 1 D N
6 (3, 1) 0 0/1 NA E NA 26 (1, 3) 1 1/2 1 D N
7 (1, 4) 1 1/1 3 E Y 27 (2, 1) 0 0/2 1 E N
8 (3, 4) 1 1/1 3 D N 28 (1, 3) 0 1/3 1 R N
9 (1, 4) 0 1/2 3 E Y 29 (1, 3) 0 1/4 1 E N
10 (3, 3) 0 0/1 2 E N 30 (2, 2) 0 0/3 1 R N
11 (4, 3) 0 0/1 2 E N 31 (2, 2) 0 0/4 1 E N
12 (3, 4) 1 2/2 3 D N 32 (3, 1) 0 1/3 1 R N
13 (3, 3) 0 0/2 2 E N 33 (3, 1) 0 1/4 1 E N
14 (4, 3) 1 1/2 2 D N 34 (1, 4) 0 1/5 1 R N
15 (2, 4) 1 1/1 3 D N 35 (1, 4) 0 1/6 1 E N
16 (2, 3) 0 0/1 3 E N 36 (2, 3) 0 1/3 1 R N
17 (1, 4) 0 1/3 3 E Y 37 (2, 3) 1 2/4 1 D N
18 (4, 2) 0 0/1 3 E N 38 (1, 4) 1 2/7 1 D Y
19 (3, 3) 1 1/3 3 D N 39 (3, 1) 0 1/4 3 E N
20 (1, 4) 0 1/4 3 E N 40 (4, 1) 0 1/2 3 R N
The first six patients were treated in the start-up phase. Actions E ,R,D denote the decisions of dose
escalation, retainment, and de-escalation, respectively. The incoherence indicator is calculated based on the
estimated toxicity order.
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